Genetic Framework Flags Safety Risks for Inflammatory Bowel Disease Drug Targets
A new genetics-based framework systematically flags potential safety risks for inflammatory bowel disease drug targets before broad clinical exposure.
A new genetics-based framework systematically flags potential safety risks for inflammatory bowel disease drug targets before broad clinical exposure.
A 15-year analysis of 454 herbal medicine adverse event reports at a Korean integrative medical center shows that nearly a ...
An analysis of six years of FDA adverse event reports finds disproportionately high reporting odds of hair loss among patients ...
A case report in BMC Psychiatry documents a 45-year-old man with no psychiatric history who developed cognitive impairment, affective instability, ...
A large pharmacovigilance analysis of over 30,000 adverse event reports confirms riociguat's known risks and uncovers new safety signals, including ...
A pharmacovigilance analysis of US and Japanese adverse event databases finds that PD-1 and PD-L1 checkpoint inhibitors show a robust, ...
A new international study combining clinical data and global pharmacovigilance databases shows that dermatologic side effects of the breast cancer ...
A multidisciplinary evaluation of four leading AI chatbots answering real patient questions about pregabalin found high accuracy but troubling failures ...
A new EASO position statement argues that Europe's health systems must be restructured around five pillars to deliver the benefits ...
A major review finds AI is already improving clinical trial recruitment and adjudication but warns that most applications still lack ...
© 2025 Scienmag - Science Magazine
© 2025 Scienmag - Science Magazine